What you should know:
1. The whistleblower complaint accused Janssen of giving away services that “carry significant value” and would normally cost more than $1,200 per consultative session in exchange for growing the drug lines of Remicade, a Crohn’s disease drug, and Simponi, an ulcerative colitis drug.
2. The complaint alleged that Janssen “effectively becomes a business partner … helping these practices establish, operate and grow their infusion business so they continue using and buying Remicade and Simponi.”
3. Janssen allegedly also provided similar services to rheumatology practices. These practices would also buy Remicade and Simponi.
4. The whistleblower lawsuit was originally filed in 2016. The U.S. Department of Justice and several state attorney offices declined to intervene. The lawsuit was reintroduced in April 2019 by the whistleblower, a former employee.
5. Johnson & Johnson disclosed the reintroduced lawsuit in its annual 10-K filing Feb. 10.
Note: Becker’s reached out to Johnson & Johnson for a comment. We will update this story when we hear back.
More articles on gastroenterology:
4 orthopedic, spine ASCs recently opened or announced
Banner Health to acquire Phoenix orthopedic practice, add 18 physicians
Surgeon performs Florida ASC’s first knee replacement with Navio robot
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.